Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Kaplan-Meier methods estimated overall survival (OS) and duration of response (DOR). DOR was defined from the time of initial response to progression, death, or last follow-up. Median follow-up was ...

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Important Readouts in 2026 for Phase 3 CTCL Study Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

ORLANDO, Fla. — Up to half of all people with severe chronic hand eczema (CHE) who apply delgocitinib cream (Anzupgo) to their hands twice a day have had a profound response to treatment, and about a ...

The show is over for Pulmocide’s phase 3 trial after patients who received its investigational inhaled antifungal had lower response rates and a higher number of deaths than those in the control arm.

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed the study, ...